Show simple item record

dc.contributor.authorYlä-Herttuala S
dc.contributor.authorBridges C
dc.contributor.authorKatz MG
dc.contributor.authorKorpisalo P
dc.date.accessioned2017-06-26T11:48:52Z
dc.date.available2017-06-26T11:48:52Z
dc.date.issued2017
dc.identifier10.1093/eurheartj/ehw547fi_FI
dc.identifier.issn0195-668X
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/2624
dc.descriptionArticle
dc.description.abstractChronic cardiovascular diseases are significant health problems. Although current treatment strategies have tremendously improved disease management, up to 30% of these patients cannot be successfully treated with current treatment approaches and new treatment strategies are clearly needed. Gene therapy and therapeutic vascular growth may provide a new treatment option for these patients. Several growth factors, like vascular endothelial growth factors, fibroblast growth factors and hepatocyte growth factor have been tested in clinical trials. However, apart from demonstration of increased vascularity, very few results with clinical significance have been obtained. Problems with gene transfer efficiency, short duration of transgene expression, selection of endpoints, and suboptimal patients for gene therapy have been recognized. Ongoing gene therapy trials have included improvements in study protocols, vector delivery and endpoints, addressing the identified problems. Better, targeted delivery systems and new, more optimal growth factors have been taken to clinical testing. Recent advances in these areas will be discussed and the concept of angiogenic therapy as a sole treatment is re-evaluated. A combination with regenerative therapies or standard revascularization operations might be needed to improve tissue function and clinical benefits.fi_FI
dc.language.isoENfi_FI
dc.publisherOxford University Press (OUP)fi_FI
dc.relation.ispartofseriesEUROPEAN HEART JOURNAL
dc.relation.urihttp://dx.doi.org/10.1093/eurheartj/ehw547fi_FI
dc.rightsAll rights reserved
dc.subjectGene therapyfi_FI
dc.subjectAngiogenesisfi_FI
dc.subjectCoronary heart diseasefi_FI
dc.subjectPeripheral arterial diseasefi_FI
dc.subjectHeart failurefi_FI
dc.subjectGene deliveryfi_FI
dc.subjectGrowth factorsfi_FI
dc.titleAngiogenic gene therapy in cardiovascular diseases: dream or vision?fi_FI
dc.typehttp://purl.org/eprint/type/JournalArticle
dc.description.versionfinal draftfi_FI
dc.contributor.departmentA.I. Virtanen -instituutti
uef.solecris.id47673777
eprint.statushttp://purl.org/eprint/status/PeerReviewedfi_FI
dc.type.publicationinfo:eu-repo/semantics/article
dc.rights.accessrights© Authorsfi_FI
uef.citationinfo.pages1365-1371
dc.relation.doi10.1093/eurheartj/ehw547
dc.description.reviewstatushttp://purl.org/eprint/status/PeerReviewed
dc.format.pagerange1365-1371
dc.relation.issn0195-668X
dc.relation.issue18
dc.relation.volume38
dc.rights.accesslevelopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record